Keywords: PET/MR, Cancer, Prostate Cancer, Metabolic Imaging, Hyperpolarized MRMany advanced prostate cancer patients receiving anti-androgens (Enzalutamide) as the first line of treatment, develop resistance which relapses into metastatic castrate-resistant prostate cancer (mCRPC). Treatment options for mCRPC patients are limited and continue to pose a significant oncological challenge with an alarming low survival rate of only 28%. The overarching goal of this research is thus to develop personalized metabolic imaging modality to target treatment strategies of different metabolic sub-types of prostate cancer by targeting pyruvate-to-lactate metabolism by hyperpolarized [1-13C]-pyruvate MR and fatty acid oxidation by 18F-FPIA PET.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords